[Federal Register Volume 59, Number 149 (Thursday, August 4, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-19054]


[[Page Unknown]]

[Federal Register: August 4, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

 

Controlled Substances: Proposed Aggregate Production Quotas for 
1995

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed aggregate production goals for 1995.

-----------------------------------------------------------------------

SUMMARY: This notice proposes initial 1995 aggregate production quotas 
for controlled substances in Schedules I and II of the Controlled 
Substances Act.

DATES: Comments or objections should be received on or before September 
6, 1994.

ADDRESSES: Send comments or objections to the Administrator, Drug 
Enforcement Administration, Washington, DC 20537, Attn: DEA Federal 
Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & 
Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act 
(21 U.S.C. 826) requires that the Attorney General establish aggregate 
production quotas for each basic class of controlled substance listed 
in Schedules I and II. This responsibility has been delegated to the 
Administrator of the DEA by Section 0.100 of Title 28 of the Code of 
Federal Regulations. The Administrator, in turn, has redelegated this 
function to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 
1994).

    The quotas are to provide adequate supplies of each substance for: 
(1) The estimated medical, scientific, research, and industrial needs 
of the United States; (2) lawful export requirements; and (3) the 
establishment and maintenance of reserve stocks.
    In determining the below listed proposed 1995 aggregate production 
quotas, the Deputy Administrator considered the following factors: (1) 
Total actual 1993 and estimated 1994 and 1995 net disposals of each 
substance by all manufacturers; (2) estimates of 1994 year end 
inventories of each substance and of any substance manufactured from it 
and trends in accumulation of such inventories; and (3) projected 
demand as indicated by procurement quota applications filed pursuant to 
Sec. 1303.12 of Title 21 of the Code of Federal Regulations.
    Pursuant to Sec. 1303.23(c) of Title 21 of the Code of Federal 
Regulations, the Deputy Administrator of the DEA will, in early 1995, 
adjust aggregate production quotas and individual manufacturing quotas 
allocated for the year based upon 1994 year-end inventory and actual 
1994 disposition data supplied by quota recipients for each basic class 
of Schedule I or II controlled substance.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), 
delegated to the Administrator of the DEA by Section 0.100 of Title 28 
of the Code of Federal Regulations, and redelegated to the Deputy 
Administrator pursuant to 59 FR 23637 (May 6, 1994), the Deputy 
Administrator hereby proposes that the aggregate production quotas for 
1995 for the following controlled substances, expressed in grams of 
anhydrous acid or base, be established as follows: 

------------------------------------------------------------------------
                                                               Proposed 
                        Basic class                          1995 quotas
------------------------------------------------------------------------
                               Schedule I                               
                                                                        
------------------------------------------------------------------------
Acetylmethadol.............................................            2
Aminorex...................................................            2
Bufotenine.................................................           10
Cathinone..................................................            4
Difenoxin..................................................       14,000
2, 5-Dimethoxyamphetamine..................................   15,650,000
Dimethylamphetamine........................................            2
N-Ethylamphetamine.........................................            4
Lysergic acid diethylamide.................................           41
Mescaline..................................................            2
4-Methoxyamphetamine.......................................           12
4-Methylaminorex...........................................            2
3-Methylfentanyl...........................................           12
Methaqualone...............................................            2
Methcathinone..............................................            9
3, 4-Methylenedioxyamphetamine.............................           12
3, 4-Methylenedioxy-N-ethylamphetamine.....................            2
3, 4-Methylenedioxymethamphetamine.........................           12
Normorphine................................................            2
Tetrahydrocannibinols......................................       35,000
Thiophene Analog of Phencyclidine..........................           10
                                                                        
------------------------------------------------------------------------
                               Schedule II                              
                                                                        
------------------------------------------------------------------------
Alfentanil.................................................        7,000
Amobarbital................................................            5
Amphetamine................................................      635,000
Cocaine....................................................      550,000
Codeine (for sale).........................................   67,312,000
Codeine (for conversion)...................................   16,181,000
Desoxyephedrine 900,000 grams of levodesoxyephedrine for                
 use in a noncontrolled, nonprescription product and 20                 
 grams for methamphetamine.................................      900,020
Dextropropoxyphene.........................................  124,012,000
Dihydrocodeine.............................................      202,000
Diphenoxylate..............................................      688,000
Ecgonine (for conversion)..................................      650,000
Fentanyl...................................................       76,000
Hydrocodone................................................    8,474,000
Hydromorphone..............................................      393,000
Levo-alpha-acetylmethadol..................................      200,000
Levorphanol................................................        8,000
Meperidine.................................................    8,637,000
Methadone..................................................    3,779,000
Methadone (for conversion).................................      364,000
Methadone Intermediate (for sale)..........................      300,000
Methadone Intermediate (for conversion)....................    4,393,000
Methylphenidate............................................    7,935,000
Morphine (for sale)........................................    7,612,000
Morphine (for conversion)..................................   78,105,000
Noroxymorphone (for sale)..................................       21,000
Noroxymorphone (for conversion)............................    3,500,000
Opium......................................................    1,118,000
Oxycodone (for sale).......................................    3,613,000
Oxycodone (for conversion).................................        6,200
Oxymorphone................................................        2,500
Pentobarbital..............................................   15,706,000
Phencyclidine..............................................           52
Phenylacetone (for conversion).............................    3,528,000
Secobarbital...............................................      480,000
Sufentanil.................................................          700
Thebaine...................................................    9,383,000
------------------------------------------------------------------------

    Aggregate production quotas for all other Schedules I and II 
controlled substances included in Secs. 1308.11 and 1308.12 of Title 21 
of the Code of Federal Regulations are established at zero.
    All interested persons are invited to submit their comments and 
objections in writing regarding this proposal. A person may object to 
or comment on the proposal relating to any of the above-mentioned 
substances without filing comments or objections regarding the others. 
If a person believes that one or more of these issues warrant a 
hearing, the individual should so state and summarize the reasons for 
this belief.
    In the event that comments or objections to this proposal raise one 
or more issues which the Deputy Administrator finds warrant a hearing, 
the Deputy Administrator shall order a public hearing by notice in the 
Federal Register, summarizing the issues to be heard and setting the 
time for the hearing.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866. This action has been analyzed in accordance with 
the principles and criteria contained in Executive Order 12612, and it 
has been determined that this matter does not have sufficient 
federalism implications to warrant the preparation of a Federalism 
Assessment.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C., 601, et seq. 
The establishment of annual aggregate production quotas for Schedules I 
and II controlled substances is mandated by law and by international 
treaty obligations. While aggregate production quotas are of primary 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Accordingly, the Deputy Administrator 
has determined that this action does not require a regulatory 
flexibility analysis.

    Dated: July 28, 1994.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 94-19054 Filed 8-3-94; 8:45 am]
BILLING CODE 4410-09-M